Medical device expert Terumo Corporation has reached an agreement with WuXi Biologics to acquire its 13,000m2 drug product plant in Leverkusen, Germany.
The €150m deal falls in line with Terumo's plans to expand its global pharmaceutical and medical device CDMO business, which currently develops prefilled syringes and drug delivery devices.
This will be Terumo's first overseas CDMO production base, and will expand the company's supply chain efficiency and production capacity.
Staffed with around 150 skilled personnel, the GMP*3 drug product plant is equipped with facilities suitable for the development and production of prefilled syringe and vial products.
Via this acquisition, Terumo hopes to address the growing demand for CDMO services within the European and US regions — which is primarily driven by the rapid growth of the biopharmaceutical sector.
This novel capacity adds to its current CDMO production bases at its Kofu, Fujinomiya, and Yamaguchi sites, with both the Kofu and Yamaguchi sites undergoing recent expansions to cater to its pharmaceutical customers.
"The acquisition of the drug product plant is a pivotal step in enhancing the competitiveness of our CDMO business, and we are thrilled to have reached an agreement with WuXi Biologics,” said Hikaru Samejima, CEO of Terumo Corporation.
“By integrating the high-quality and stable production operations of the Leverkusen plant and the exceptional talent supporting it with Terumo, we are confident that we will significantly elevate the global responsiveness of our CDMO business."